Webinar: Engineering AAV Lead Vectors for Gene Therapy
The recombinant adeno-associated virus (rAAV) vector design affects not only the duration and localisation of...
SIRION Biotech was thrilled to receive its trophy after winning a Gold Stevie Award at this year’s American Business Awards, winning in the category Fastest Growing Company of the Year – Up to 100 Employees, after achieving record growth in the previous year.
SIRION Biotech is a globally active technology provider with a strong customer base in the fields of cancer research, neurosciences, regenerative medicines, gene therapy, CAR T-cell development and R&D of new vaccination methods.
Founded in 2007 at the IZB in Martinsried near Munich, Germany, the company was designed to shift the paradigm of viral vector technologies and supplies.
For more information, please fill out the enquiry form attached to this page.
The recombinant adeno-associated virus (rAAV) vector design affects not only the duration and localisation of...
World leader in viral vector-based gene delivery technologies for gene & cell therapy, SIRION Biotech,...
Sirion Biotech is pleased to announce that Mustang Bio is utilising its proprietary transduction enhancer,...
Through this license agreement, SIRION Biotech GmbH granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™....